Details of Data Requests to Use Johnson and Johnson Data

Request listing updated daily

All Requests

The YODA Project posts proposals once data access has been granted or denied.

Approved Requests

The YODA Project posts approved proposals once data access has been granted.

Withdrawn Requests

The following data requests could not be fulfilled due to patient privacy concerns, data element availability, data security concerns, or lack of research proposal clarity. The YODA Project posts withdrawn/unapproved proposals at the time the decision is made.

Filters list

YODA Protocol Number 2022-5104
Product(s) of Interest REMICADE® (Infliximab) SIMPONI® (Golimumab) STELARA® (Ustekinumab)
No. Trials Provided 6
Published Publications Available! See more below

Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis

Principal Investigator

Rirong Chen The First Affiliated Hospital of Sun Yet-sen University

Reports & Publications

UEG Journal 2023
Citations
Altmetrics
Precision Clinical Medicine 2023
Citations
Altmetrics
Int. Immunophar 2024
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2022-5104 Proposal (PDF) Protocol #2022-5104 Review (PDF) Protocol #2022-5104 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4846
Product(s) of Interest ERLEADA® (Apalutamide)
No. Trials Provided 1
Ongoing Publication Available!

External Validation of a Prognostic Model of Overall Survival In Men with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator

Susan Halabi Duke University

Reports & Publications

J Clin Oncol . 2023
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4846 Proposal (PDF) Protocol #2021-4846 Review (PDF) Protocol #2021-4846 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4822
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 2
Ongoing Publication Available!

Comparative Efficacy of Ustekinumab and Infliximab on One Year Outcomes Among Biologic-nave Induction Responders in Crohn’s Disease

Principal Investigator

Neeraj Narula McMaster University

Reports & Publications

Inflamm Bowel Dis. 2022
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4822 Proposal (PDF) Protocol #2021-4822 Review (PDF) Protocol #2021-4822 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4779
Product(s) of Interest REMICADE® (Infliximab) STELARA® (Ustekinumab) SIMPONI® (Golimumab)
No. Trials Provided 6
Published Publications Available! See more below

Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease

Principal Investigator

Neeraj Narula Hamilton Health Sciences

Reports & Publications

Clin Gastroenterol Hepatol 2022
Citations
Altmetrics
Inflamm Bowel Dis 2023
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4779 Proposal (PDF) Protocol #2021-4779 Review (PDF) Protocol #2021-4779 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4778
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Published Publication Availible!

Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease

Principal Investigator

Neeraj Narula Hamilton Health Sciences

Reports & Publications

Am J Gastroenterol 2022
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4778 Proposal (PDF) Protocol #2021-4778 Review (PDF) Protocol #2021-4778 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4757
Product(s) of Interest REMICADE® (Infliximab)
No. Trials Provided 2
Published Publication Available!

A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis.

Principal Investigator

Neeraj Narula Hamilton Health Sciences

Reports & Publications

Dig Dis Sci. 2023
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4757 Proposal (PDF) Protocol #2021-4757 Review (PDF) Protocol #2021-4757 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4684
Product(s) of Interest STELARA® (Ustekinumab)
No. Trials Provided 3
Published Publications Available!

Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease

Principal Investigator

Neeraj Narula McMaster University

Reports & Publications

Aliment Pharmacol Ther. 2022
Citations
Altmetrics
J Chron’s Colitis. 2022
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4684 Proposal (PDF) Protocol #2021-4684 Review (PDF) Protocol #2021-4684 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4637
Product(s) of Interest SPRAVATO® (Esketamine)
No. Trials Provided 3
Published Publication Available!

Data-sharing and re-analysis for main studies assessed by the European Medicines Agency – a cross-sectional study on EPARs

Principal Investigator

Florian Naudet University of Rennes

Reports & Publications

BMC Med 2022
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4637 Proposal (PDF) Protocol #2021-4637 Review (PDF) Protocol #2021-4637 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4602
Product(s) of Interest STELARA® (Ustekinumab) REMICADE® (Infliximab)
No. Trials Provided 4
Published Publication Available!

Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease

Principal Investigator

Neeraj Narula McMaster University

Reports & Publications

Journal of Chron’s & Colitis
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4602 Proposal (PDF) Protocol #2021-4602 Review (PDF) Protocol #2021-4602 Due Diligence Assessment (PDF)
YODA Protocol Number 2021-4599
Product(s) of Interest DARZALEX® (Daratumumab)
No. Trials Provided 6
Published Publication Available!

Outcomes with Early versus Late Response to Daratumumab in Patients with Refractory/Relapsed or Newly Diagnosed Multiple Myeloma

Principal Investigator

Jiasheng Wang MetroHealth Medical Center

Reports & Publications

Leuk Lymphoma 2022
Citations
Altmetrics

Protocol & Associated Materials

Protocol #2021-4599 Proposal (PDF) Protocol #2021-4599 Review (PDF) Protocol #2021-4599 Due Diligence Assessment (PDF)
of